Table 1. Patient disposition.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; N/A, not applicable

	Patients	Treatment courses
Treated with immunotherapies for solid tumor and hematologic cancers in study period 2014-2019	70,605	N/A
Initiated treatment with immunotherapy in 2014 with no related treatment 180 days prior	70,534	N/A
Treatment with one of the treatment courses	70,534	87,439
Age ≥ 18 years at the index date of a treatment course	70,528	87,342
Excluded due to benign tumor or missing cancer diagnosis prior to initiation of a treatment course	69,800	86,449
Excluded due to grade 3 or 4 AST/ALT elevation within 30 days prior to initiation of a treatment course	69,448	85,799
Patients with solid tumor	69,140	85,433